open access

Vol 12, No 1 (2016)
Review paper
Published online: 2016-05-02
Get Citation

The role of anthracyclines and dose dense therapy in an adjuvant setting, in HER2-positive early breast cancer, in clinical practice

Renata Duchnowska, Ewa Chmielowska, Joanna Streb, Małgorzata Chudzik, Bogumiła Czartoryska-Arłukowicz, Małgorzata Litwiniuk, Wojciech P. Olszewski, Tadeusz Pieńkowski, Ewa Kalinka-Warzocha, Iwona Głogowska
Oncol Clin Pract 2016;12(1):8-11.

open access

Vol 12, No 1 (2016)
REVIEW ARTICLES
Published online: 2016-05-02

Abstract

Anthracyclines are antitumor antibiotics that are widely used in the treatment of breast cancer. A meta-analysis of previous randomised studies suggests a special role of anthracyclines in the adjuvant treatment of patients with HER2-positive breast cancer. In this group, anthracycline-based regimens have largely replaced CMF (cyclophosphamide, methotrexate, fluorouracil) schedule. More recently, regimens including anthracyclines with taxanes in combination with an anti-HER2 monoclonal antibody trastuzumab have found wide application in HER2-positive patients with higher risk of recurrence. A major contraindication to the use of anthracyclines is an increased risk of cardiac complications. In this article we present the current role of anthracyclines in adjuvant treatment of patients with HER2-positive breast cancer.

Abstract

Anthracyclines are antitumor antibiotics that are widely used in the treatment of breast cancer. A meta-analysis of previous randomised studies suggests a special role of anthracyclines in the adjuvant treatment of patients with HER2-positive breast cancer. In this group, anthracycline-based regimens have largely replaced CMF (cyclophosphamide, methotrexate, fluorouracil) schedule. More recently, regimens including anthracyclines with taxanes in combination with an anti-HER2 monoclonal antibody trastuzumab have found wide application in HER2-positive patients with higher risk of recurrence. A major contraindication to the use of anthracyclines is an increased risk of cardiac complications. In this article we present the current role of anthracyclines in adjuvant treatment of patients with HER2-positive breast cancer.

Get Citation

Keywords

breast cancer; HER2; anthracyclines

About this article
Title

The role of anthracyclines and dose dense therapy in an adjuvant setting, in HER2-positive early breast cancer, in clinical practice

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 1 (2016)

Article type

Review paper

Pages

8-11

Published online

2016-05-02

Bibliographic record

Oncol Clin Pract 2016;12(1):8-11.

Keywords

breast cancer
HER2
anthracyclines

Authors

Renata Duchnowska
Ewa Chmielowska
Joanna Streb
Małgorzata Chudzik
Bogumiła Czartoryska-Arłukowicz
Małgorzata Litwiniuk
Wojciech P. Olszewski
Tadeusz Pieńkowski
Ewa Kalinka-Warzocha
Iwona Głogowska

References (35)
  1. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013; 34(15): 1102–1111.
  2. Curigliano G, Cardinale D, Suter T, et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7: vii155–vii166.
  3. Robson D, Verma S. Anthracyclines in early-stage breast cancer: is it the end of an era? Oncologist. 2009; 14(10): 950–958.
  4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005; 365(9472): 1687–1717.
  5. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008; 100(1): 14–20.
  6. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011; 29(12): 1578–1586.
  7. Ramakrishna N, Temin S, Chandarlapaty S, et al. American Society of Clinical Oncology. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(19): 2078–2099.
  8. Samuel JA, Wilson JW, Bandos H et al. National Surgical Adjuvant Breast and Bowel Project (NSABP), NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. SABCS 2014; S3-02.
  9. Jassem J, Krzakowski K. Rak piersi. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 rok. Via Medica, Gdańsk 2013: 211–265.
  10. Ewer MS, Swain SM, Cardinale D, et al. Cardiac dysfunction after cancer treatment. Tex Heart Inst J. 2011; 38(3): 248–252.
  11. Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273–1283.
  12. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16): 1673–1684.
  13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16): 1659–1672.
  14. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007; 25(25): 3859–3865.
  15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783–792.
  16. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet Oncology. 2014; 15(6): 640–647.
  17. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010; 28(12): 2024–2031.
  18. Untch M, Loibl S, Bischoff J, et al. German Breast Group (GBG), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2): 135–144.
  19. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012; 13(9): 869–878.
  20. Bayraktar S, Gonzalez-Angulo AM, Lei X, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012; 118(9): 2385–2393.
  21. Cortes J, Di Cosimo S, Climent MA, et al. Spanish Breast Cancer Cooperative Group SOLTI. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res. 2009; 15(1): 307–314.
  22. Baselga J, Manikhas A, Cortés J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2014; 25(3): 592–598.
  23. Martín M, Sánchez-Rovira P, Muñoz M, et al. GEICAM. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol. 2011; 22(12): 2591–2596.
  24. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012(4): CD006243.
  25. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006; 24(34): 5381–5387.
  26. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009; 27(8): 1177–1183.
  27. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011; 29(34): 4491–4497.
  28. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362(6): 513–520.
  29. Haviland JS, Owen JR, Dewar JA, et al. START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11): 1086–1094.
  30. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015; 372(2): 134–141.
  31. Shulman LN, Berry DA, Cirrincione CT, et al. Comparision of doxorubicin and cyclophosphamid versus single agent paclitaksel as adjuvant therapy for breast cancer in woman with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014; 32: 2311–2317.
  32. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005; 97(23): 1724–1733.
  33. Del Mastro L, De Placido S, Bruzzi P, et al. Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015; 385(9980): 1863–1872.
  34. Baldini E. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Annals of Oncology. 2003; 14(2): 227–232.
  35. Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol. 2008; 26(8): 1216–1222.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl